Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 9:10.1002/ajh.26619. Online ahead of print. doi: 10.1002/ajh.26619

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Live SARS‐CoV‐2 neutralization of delta variant in HEK cell line at T3. There is a slight reduction in neutralization of delta variant in FL patients treated with ICT (A) compared to HC. There is significantly lower neutralization of delta variant in WM patients treated with BTKi (B) compared to both HC and TN. Neutralization activity correlates well with anti‐spike IgG (C). A p < 0.03 was considered statistically significant in A and <.01 in B after Bonferroni correction. BTKi, BTKi‐treated cohort; HC, healthy controls; ICT, immunochemotherapy‐treated cohort; IgG, immunoglobulin G; MFI, delta mean fluorescence intensity; TN, treatment naïve cohort. **p < 0.01; ***p < 0.001; ****p < .0001.